Immunic, Inc

1200 Avenue of the Americas, Suite 200
New York, NY 10036, USA

Phone: +49 89 2080 477 00
Email: info@imux.com

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing, Germany

Phone: +49 89 2080 477 00
Email: info@imux.com

Jessica

September 8, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in September

NEW YORK, September 8, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing...

Read More
August 20, 2020

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

NEW YORK, August 20, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
August 5, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

NEW YORK, August 4, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing...

Read More
August 3, 2020

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock

NEW YORK, August 3, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing...

Read More
August 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

– Study Meets Primary and Key Secondary Endpoints with High Statistical Significance...

Read More
July 30, 2020

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

NEW YORK, July 30, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
July 29, 2020

Immunic, Inc. to Participate in Investor Conferences in August

NEW YORK, July 29, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
June 22, 2020

Immunic, Inc. to Join Russell 3000® Index

NEW YORK, June 22, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
June 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

NEW YORK, June 15, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
June 10, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

NEW YORK, June 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical...

Read More
June 10, 2020

Immunic, Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, June 9, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
June 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

NEW YORK, June 9, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
May 29, 2020

Immunic, Inc. to Participate in Investor and Industry Conferences in June

NEW YORK, May 29, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company...

Read More
May 19, 2020

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

– Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well...

Read More